CV TECHNOLOGIES, INC. – Trademark Portfolio
Entity Type: 03
CV TECHNOLOGIES, INC. holds 32 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 30 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 3 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include COLD-FX. The owner is based in Edmonton Alberta T6G 1K8.
Ste #308 Campus Towers, 8625-112 Street
Edmonton Alberta T6G 1K8 , CA
Showing of trademarks Trademarks
Trademark Classifications
CV TECHNOLOGIES, INC.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Apparatus for lighting, heating, steam generating, cooking, refrigerating, drying
Frequently Asked Questions
How many trademarks does CV TECHNOLOGIES, INC. have?
CV TECHNOLOGIES, INC. has 32 U.S. trademarks filed with the USPTO. Of these, 2 registered, 23 abandoned, 7 cancelled.
What trademark classes does CV TECHNOLOGIES, INC. file in?
CV TECHNOLOGIES, INC. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 11 (Environmental Control). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are CV TECHNOLOGIES, INC.'s most well-known trademarks?
CV TECHNOLOGIES, INC.'s registered trademark portfolio includes well-known marks such as COLD-FX. These are among 2 currently registered trademarks in the portfolio.
What is CV TECHNOLOGIES, INC.'s trademark registration success rate?
CV TECHNOLOGIES, INC. has a 6% trademark registration rate, with 2 out of 32 resolved applications resulting in successful registration. Currently, 0 applications are pending review.